RecruitingPHASE1, PHASE2NCT03850574
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Studying Acute myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aptose Biosciences Inc.
- Principal Investigator
- Naval Daver, MDM.D. Anderson Cancer Center
- Intervention
- Tuspetinib(drug)
- Enrollment
- 240 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (30)
- The Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- University of California Irvine, Irvine, California, United States
- UCSD Moores Cancer Center, La Jolla, California, United States
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Stanford Cancer Center, Palo Alto, California, United States
- University of California, Davis, Sacramento, California, United States
- Yale University, New Haven, Connecticut, United States
- University of Miami - Miller School of Medicine, Miami, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
- The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- MD Anderson Cancer Center, Huston, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03850574 on ClinicalTrials.govOther trials for Acute myelomonocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06994676A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasCrossbow Therapeutics, Inc.
- RECRUITINGPHASE2NCT06680661ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisLeland Metheny
- RECRUITINGPHASE2NCT06778187Oral-ATO for TP53-mutated Myeloid MalignanciesThe University of Hong Kong
- RECRUITINGPHASE1NCT06247787A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyChildren's Oncology Group
- RECRUITINGNCT06111612Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT05807932Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE1NCT05636514Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSClinical Hub for Interventional Research (CHOIR)
- RECRUITINGPHASE1, PHASE2NCT05092451Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesM.D. Anderson Cancer Center